ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1619 • 2014 ACR/ARHP Annual Meeting

    Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs

    David Drubin1, Xiang Guo2, Linglin Yang3, Rong Zeng3, Yuling Wu3, Mustimbo EliPollard Roberts3, Reynald Lescarbeau1, Aaron Van Hooser1, Michael Macoritto1, Michelle Petri4 and Wendy White5, 1Selventa, Cambridge, MA, 2Translational Sciences, MedImmune LLC, Gaithersburg, MD, 3MedImmune LLC, Gaithersburg, MD, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Translational Sciences, MedImmune, Gaithersburg, MD

    Background/Purpose Interferons (IFNs) have long been implicated in the pathogenesis of systemic lupus erythematosus (SLE). However, the specific consequences of the IFN activity have not…
  • Abstract Number: 1618 • 2014 ACR/ARHP Annual Meeting

    Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties

    Jing Yao Leong1, Joo Guan Yeo1, Thaschawee Arkachaisri2 and Jinhua Lu3, 1Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, 2Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 3Microbiology Department, National University of Singapore, Singapore, Singapore

    Background/Purpose Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with the development of auto-antibodies particularly against nuclear antigens. Previous studies have revealed the possible…
  • Abstract Number: 1617 • 2014 ACR/ARHP Annual Meeting

    Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes

    Zhongbo Jin1, Mark A. Jensen2, Jessica M. Dorschner1, Danielle Vsetecka1, Shreyasee Amin3, Ashima Makol4, Floranne C. Ernste5, Thomas Osborn6, Kevin G. Moder4, Vaidehi Chowdhary3 and Timothy B. Niewold1, 1Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 2Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, 6Dept of Rheumatology, Mayo Clinc, Rochester, MN

    Background/Purpose Type I interferon (IFN) is a primary pathogenic factor in human systemic lupus erythematosus (SLE).  IFN gene expression signatures have been observed in whole blood and mixed peripheral…
  • Abstract Number: 1598 • 2014 ACR/ARHP Annual Meeting

    Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis

    Hanna Przepiera-Bedzak1, Katarzyna Fischer2 and Marek Brzosko1, 1Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, 2Independent Laboratory of Rheumatic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland

    Background/Purpose In recent years, increased incidences of metabolic disorders have been observed in patients with systemic inflammatory rheumatic diseases. Fetuin-A, Intercellular Adhesion Molecule -1(ICAM-1) and…
  • Abstract Number: 1599 • 2014 ACR/ARHP Annual Meeting

    Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes

    Megan E. B. Clowse, Rheumatology, Duke University Medical Center, Durham, NC

    Background/Purpose:   While it has long been reported that rheumatoid arthritis (RA) improves with pregnancy, there is very limited information about ankylosing spondylitis (AS) or…
  • Abstract Number: 1597 • 2014 ACR/ARHP Annual Meeting

    Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial

    Frank Zhang1, Thomas Tencer1, Stan Li2 and Vibeke Strand3, 133 Technology Drive, Celgene Corporation, Warren, NJ, 2Celgene Corporation, Warren, NJ, 3Biopharmaceutical Consultant, Portola Valley, CA

    Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the aberrant immune response that causes the joint symptoms, systemic inflammation, and skin…
  • Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)

    Saedis Saevarsdottir1, Michele Santacatterina2, Carl Turesson3, Helena Forsblad4, Lennart Jacobsson4 and Staffan Lindblad5, 1Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
  • Abstract Number: 1595 • 2014 ACR/ARHP Annual Meeting

    Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States

    Thomas Tencer1, Zoe Clancy1, Helene Cawston2, Sandrine Cure3 and Frank Zhang1, 133 Technology Drive, Celgene Corporation, Warren, NJ, 2OptumInsight, Nanterre, France, 3OptumInsight, Uxbridge, United Kingdom

    Background/Purpose: In the treatment of psoriatic arthritis (PsA), switching between alternative biologic treatments is common. A cost-effectiveness model was developed to assess the impact of…
  • Abstract Number: 1594 • 2014 ACR/ARHP Annual Meeting

    Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis

    Doquyen H. Huynh1, Carol J. Etzel2,3, Vanessa Cox4, Philip J. Mease5 and Arthur Kavanaugh6, 1Rheumatology, UC San Diego School of Medicine, San Diego, CA, 2PO Box 786, Corrona, LLC., Southborough, MA, 3Department of Epidemiology, UT MD Anderson, Houston, TX, 4CORRONA, Inc, Southborough, MA, 5CORRONA, Seattle, WA, 6UCSD School of Medicine, La Jolla, CA

    Background/Purpose: The increased use of tumor necrosis factor inhibitors (TNFi) has improved clinical outcomes for psoriatic arthritis (PsA) patients and made low disease activity (LDA)…
  • Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting

    Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis

    Vinod Chandran1, Arane Thavaneswaran2 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
  • Abstract Number: 1592 • 2014 ACR/ARHP Annual Meeting

    Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis

    Vinod Chandran1, Arane Thavaneswaran2, Richard J. Cook3 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis that leads to progressive joint damage. Biomarkers in addition to clinical features may help…
  • Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting

    Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis

    M. Elaine Husni1, Danielle Brennan2, WH Wilson Tang3 and Stanley Hazen3, 1Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 2Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 3Cardiology, CCF, Cleveland, OH

    Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity.  Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
  • Abstract Number: 1590 • 2014 ACR/ARHP Annual Meeting

    Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

    Arthur Kavanaugh1, Adewale O. Adebajo2, Dafna D. Gladman3, Juan J. Gomez-Reino4, Stephan Hall5, Eric Lespessailles6, Philip J. Mease7, Georg A. Schett8, ChiaChi Hu9, Randall M. Stevens9 and Jürgen Wollenhaupt10, 1University of California San Diego, La Jolla, CA, 2University of Sheffield, Sheffield, United Kingdom, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology, Hospital Clinico Universitario, Santiago, Spain, 5Cabrini Health and Monash University, Melbourne, Australia, 6University of Orléans, Orléans, France, 7Swedish Medical Center and University of Washington, Seattle, WA, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9Celgene Corporation, Warren, NJ, 10Schön Klinik Hamburg Eilbek, Hamburg, Germany

    Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor that may modify the immune response, has been shown effective in psoriatic arthritis (PsA). PALACE 1 compared…
  • Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting

    Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort

    Kevin L. Winthrop1, Lang Chen2, John Baddley2, Allison Taylor3, Benjamin Chan4, Huifeng Yun5, Sarah Siegel6 and Jeffrey R. Curtis7, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Oregon Health and Science University, Portland, OR, 5Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 6Oregon Health & Science University, Portland, OR, 7The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
  • Abstract Number: 1588 • 2014 ACR/ARHP Annual Meeting

    Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life

    Diego Roger Silva1, Fabio Jennings1, Emilia Moreira1 and Jamil Natour2, 1Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 2Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose Psoriatic arthritis (PSA) is a chronic inflammatory arthritis, defined as the association of inflammatory arthropathy and skin psoriasis. The literature is still very scarce…
  • « Previous Page
  • 1
  • …
  • 1943
  • 1944
  • 1945
  • 1946
  • 1947
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology